Tecentriq and Zepzelca combination approved as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC).
The combination creates the 4th largest US wafer fabrication equipment supplier, targeting an expanded $5 billion market.
The approval of the twice-daily pill remibrutinib positions the company to challenge injectable treatments in a multi-billion dollar market.
Final regulatory hurdle cleared for the all-stock transaction, paving the way for an October 20 closing and a major expansion into Texas.
Late-breaking trial results for obefazimod show significant efficacy, positioning the first-in-class oral therapy in a competitive market.
Combination therapy approval for small cell lung cancer offers a new standard of care and a bullish signal for the pharmaceutical sector.
All-stock deal raises shareholder dilution concerns despite strategic goal of creating a diversified semiconductor equipment leader.
First-of-its-kind maintenance therapy approved for extensive-stage small cell lung cancer, a historically difficult-to-treat malignancy.